Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
34 Leser
Artikel bewerten:
(0)

CIVCO Announces 510(k) Clearance for Protura' Robotic Patient Positioning System Integration with VisionRT

CORALVILLE, Iowa, Oct. 24, 2012 /PRNewswire/ --CIVCO Medical Solutions, the leading provider of radiation oncology motion management solutions, is pleased to announce U.S. Food and Drug Administration 510(k) clearance for Protura' Robotic Patient Positioning System integration with AlignRT® 3D Imaging System.

(Logo: http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO)

"We are pleased to announce clearance to market the newest release of Protura integrated with VisionRT," said Nat Geissel, senior vice president and general manager of CIVCO's radiation oncology division. "This release allows Protura to seamlessly integrate with the AlignRT 3D surface imaging solution from VisionRT."

Protura's ability to interface with existing IGRT-enabled interfaces supports sub-millimenter patient positioning and corrections with 6 degrees of freedom. This integration allows the AlignRT user to apply calculated translation and rotational shifts automatically to the Protura system from within the simple and intuitive AlignRT interface. The Protura system provides automated, consistent and accurate 6 DOF patient alignment. Together these leading-edge technologies advance the adoption of sophisticated treatment techniques. The combination of positioning accuracy, advance technology and data consistency provided with system integration makes Protura the clinician's first choice for streamlined workflow and increased patient throughput.

About CIVCO

CIVCO Medical Solutions has over 30 years of experience and offers cutting-edge medical technology to a diverse group of medical professionals. CIVCO's Radiation Oncology (RO) division designs, manufactures and markets comprehensive motion management solutions to improve patient outcomes and increase clinical productivity for head & neck, breast, lung, abdomen, prostate and other treatment sites. RO's products include couchtops and overlays for linear accelerators and imaging systems, advanced patient immobilization solutions, robotic patient positioning, advanced fiducial markers, and immobilization/positioning equipment and consumables. The Multi-Modality Imaging (MMI) unit designs and manufactures accessories for use in diagnostic and therapeutic imaging and interventional procedures, with a strong focus on ultrasound. MMI's products range from infection control products including a wide range of ultrasound and CT covers to device guidance, positioning and electromagnetic needle tracking. CIVCO offers patients and clinicians the newest and best technology available to improve patient care.

Corporate information is available at www.CIVCO.com.

For further information please contact:
Kelly Hazelett
Marketing Communications Specialist
CIVCO Medical Solutions
Tel: 319-248-6529
kelly.hazelett@CIVCO.com

COPYRIGHT © 2012. CIVCO IS A REGISTERED TRADEMARK OF CIVCO MEDICAL SOLUTIONS. PROTURA AND ALL OTHER TRADEMARKS ARE PROPERTY OF THEIR RESPECTIVE OWNERS. NOT ALL PRODUCTS MAY BE AVAILABLE IN ALL MARKETS. ALL PRODUCTS MAY NOT BE LICENSED IN ACCORDANCE WITH CANADIAN LAW. 2012C0830

SOURCE CIVCO Medical Solutions

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.